KDR and hepatocellular carcinoma: 4) The dual anti-PD-1/VEGFR-2 therapy has a durable vessel fortification effect in HCC and could overcome treatment resistance to either treatment alone and increase long-term prognosis in both anti-PD-1 therapy-resistant and anti-PD-1 therapy-responsive HCC models (37).